Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2014-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The blockade of the femoral nerve (FNB) is the most common postoperative pain therapy after total knee replacement. Because of motor-driven weakness of the quadriceps muscle induced by femoral nerve block mobilization of Patients is difficult even dangerous (falls) and hospital stays are extended.

An alternative method could be an adductor canal block (ACB). Anatomical studies of the adductor canal demonstrated that the adductor canal contains the saphenous nerve, a pure sensory nerve for medial and anterior aspects of the knee and the tibia without any motor function.

This prospective, double-blinded, randomized study investigates the effect of FNB and ACB on quadriceps motor weakness and analgesia determined by Numeric Rating Scale (NRS).

We expect the ACB to be superior in muscle strength but equal in pain score. Both groups receive an additional anterior sciatic nerve block for complete sensory block of the operated knee

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain After TKA

NCT01922596

Mobility After Total Knee Arthroplasty

COMPLETED PHASE4

Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty

NCT02453321

Pain, Postoperative Total Knee Arthroplasty (TKA)

COMPLETED PHASE4

Continuous Adductor Canal Block for Total Knee Arthroplasty Analgesia

NCT02387021

Neuromuscular Blockade Pain Management

UNKNOWN NA

Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty

NCT03133481

Arthropathy of Knee

COMPLETED PHASE3

Analgesic Efficacy of Anterior Femoral, Genicular and Adductor Canal Nerve Block

NCT02548104

Pain, Postoperative

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Total Knee Arthroplasty Total Knee Replacement Femoral Nerve Block Adductor Canal Block

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous Adductor Canal Block (CACB)

Continuous Adductor Canal block performed with:

loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h

Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)

Continuous Femoral Nerve Block (CFNB)

Continuous Femoral Nerve Block performed with:

loading dose 0,375% Ropivacaine 15ml (56,25mg) start infusion 0,2% Ropivacaine 6ml/h

Procedure: Femoral Nerve Block. Adductor Canal Block Drug: Ropivacaine

Group Type ACTIVE_COMPARATOR

Ropivacaine

Intervention Type DRUG

Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ropivacaine

Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with knee replacement therapy and general anaesthesia
* informed consent
* preoperative "timed up and go" test performable

Exclusion Criteria

* emergency patients
* BMI \> 40 kg/m2
* American Society of Anaesthesiologists physical status (ASA) 4-5
* severe chronic obstructive pulmonary disease (COPD)
* rheumatic arthritis, diabetic Polyneuropathy, M. Parkinson
* nerve injury of lumbosacral plexus
* coagulopathy with bleeding tendency
* not capable of speaking or understanding german or english

Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No